Dishman Carbogen Amcis' Q3 FY 2025-26 Quarterly Results
- 04 Feb 2026
Result Summary
- Dishman Carbogen Amcis Ltd reported a 9.9% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 5.6%.
- Its expenses for the quarter were up by 16.9% QoQ and 11.2% YoY.
- The net profit decreased 119.9% QoQ and decreased 380.1% YoY.
- The earnings per share (EPS) of Dishman Carbogen Amcis Ltd declined at 0.83 during Q3 FY 2025-26.
Financial Statments for Q3 FY 2025-26
Total Income | 726.46 | 660.76 | 687.97 | 9.9% | 5.6% |
Total Expenses | 736.90 | 630.22 | 662.96 | 16.9% | 11.2% |
Profit Before Tax | -10.44 | 30.54 | 27.05 | -134.2% | -138.6% |
Tax | 2.53 | -34.73 | 22.42 | -107.3% | -88.7% |
Profit After Tax | -12.97 | 65.27 | 4.63 | -119.9% | -380.1% |
Earnings Per Share | -0.83 | 4.16 | 0.30 | -120.0% | -376.7% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Dishman Carbogen Amcis Ltd is a well-established company operating in the pharmaceutical industry. The company is known for providing a range of services related to drug development and manufacturing. These services include contract research and manufacturing services (CRAMS) for global pharmaceutical companies. The company focuses on developing APIs and advanced intermediates, offering its expertise across the entire drug lifecycle. As a player in the fast-evolving pharmaceutical sector, Dishman Carbogen Amcis is continually engaged in research and development to cater to the complex needs of its clients. There are no recent major developments available in the provided data or context to highlight at this time.
Revenue
In the third quarter of the fiscal year 2026 (Q3FY26), Dishman Carbogen Amcis Ltd reported a total income of ₹726.46 crores. This represents a quarter-over-quarter (QoQ) increase of 9.9% compared to the second quarter of the fiscal year 2026 (Q2FY26), where the total income was ₹660.76 crores. Additionally, there was a year-over-year (YoY) increase of 5.6% in total income compared to the third quarter of fiscal year 2025 (Q3FY25), which saw total income of ₹687.97 crores. The data indicates a positive trajectory in revenue generation over both the previous quarter and the same quarter in the previous year, highlighting the company's ability to enhance its income stream through its operations.
Profitability
The profitability metrics for Dishman Carbogen Amcis Ltd in Q3FY26 show a significant decline. The company recorded a loss before tax amounting to ₹10.44 crores, a stark contrast to the profit before tax of ₹30.54 crores in Q2FY26. This marks a decrease of 134.2% QoQ. When compared to the profit before tax of ₹27.05 crores in Q3FY25, the YoY decline is 138.6%. The impact on net profitability is evident with a loss after tax recorded at ₹12.97 crores in Q3FY26, contrasting sharply with a profit after tax of ₹65.27 crores in Q2FY26 and ₹4.63 crores in Q3FY25, indicating a QoQ decrease of 119.9% and a YoY decrease of 380.1%. This significant downturn in profitability is also reflected in the earnings per share (EPS), which fell to ₹-0.83 in Q3FY26 from ₹4.16 in Q2FY26 and ₹0.30 in Q3FY25.
Operating Metrics
The total expenses for Dishman Carbogen Amcis Ltd in Q3FY26 were reported at ₹736.90 crores, which is an increase of 16.9% QoQ compared to ₹630.22 crores in Q2FY26, and an 11.2% increase YoY from ₹662.96 crores in Q3FY25. This rise in expenses has contributed to the company's overall loss for the quarter. The tax expense in Q3FY26 stood at ₹2.53 crores, a significant shift from a tax credit of ₹34.73 crores in Q2FY26, and a tax expense of ₹22.42 crores in Q3FY25. The shift in tax-related metrics is notable and impacts the net profitability significantly. The company's operational expenditure trajectory, coupled with the revenue and tax fluctuations, provides a comprehensive picture of the operational challenges and financial dynamics faced during the quarter.